CHI’s Thirteenth Annual High-Content Analysis meeting, the premier event showcasing the latest advancements in HCA applications and technologies, returns to San Diego with a new program. Over the years we have observed the technology mature and its adoption spread into many areas of compound screening/evaluation and functional analysis. The High-Content Analysis meeting will focus on the next steps of technology development, including screening of 3D and physiologically relevant complex models, ultra-high resolution and high-throughput imaging, more advanced image analysis and data management, and new assays and applications. The co-located Second Annual Phenotypic Screening meeting will address the advantages of phenotypic screening vs. target-based screening, and focus on assay development, selection of physiologically relevant models and subsequent target identification, as well as case studies of phenotypic screens from leading pharma. Join the original High-Content Analysis event and get access to two tracks featuring a cutting-edge scientific agenda, expanded exhibit hall and technology showcases, and an offering of user group meetings and dinner courses.
Choose presentations from both programs for a customized agenda!
High-Content Analysis - View Agenda
Phenotypic Screening - View Agenda
Wednesday, February 10, 6:00-9:00 pm
Introduction to High-Content Phenotypic Screening - View Agenda
Instructor: Anthony M. Davies, Ph.D., Center Director, Translational Cell Imaging Queensland (TCIQ), Institute of Health Biomedical Innovation, Queensland University of Technology
Thursday, February 11, 6:30-9:00 pm
Expert ThinkTank: How to Meet the Need for Physiologically Relevant Assays - View Agenda
Moderator: Lisa Minor, Ph.D., President, In Vitro Strategies, LLC